Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

£656.3K GBP

Funder	National Institute for Health Research
Recipient Organization	Kleijnen Systematic Reviews Ltd
Country	United Kingdom
Start Date	Jan 15, 2021
End Date	Aug 04, 2021
Duration	201 days
Number of Grantees	1
Roles	Award Holder
Data Source	Europe PMC
Grant ID	`NIHR133012`

Grant Description

To appraise the clinical and cost effectiveness of nivolumab with ipilimumab within its marketing authorisation for untreated unresectable malignant pleural mesothelioma.